Leerink Partnrs Brokers Decrease Earnings Estimates for INSP

Inspire Medical Systems, Inc. (NYSE:INSP) – Research analysts at Leerink Partnrs dropped their Q2 2025 EPS estimates for Inspire Medical Systems in a research note issued to investors on Monday, May 5th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings of $0.19 per share for the quarter, down from their prior forecast of $0.46. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $2.16 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems’ Q4 2025 earnings at $1.24 EPS and FY2026 earnings at $3.26 EPS.

INSP has been the topic of several other reports. Royal Bank of Canada lowered their price target on shares of Inspire Medical Systems from $260.00 to $215.00 and set an “outperform” rating on the stock in a report on Tuesday, April 15th. Truist Financial lowered their price objective on Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating on the stock in a research report on Tuesday, February 11th. Morgan Stanley dropped their price objective on shares of Inspire Medical Systems from $220.00 to $200.00 and set an “overweight” rating for the company in a report on Tuesday. Stifel Nicolaus decreased their price target on Inspire Medical Systems from $190.00 to $175.00 and set a “hold” rating on the stock in a report on Monday, April 21st. Finally, KeyCorp cut their target price on shares of Inspire Medical Systems from $234.00 to $216.00 and set an “overweight” rating on the stock in a report on Monday, April 21st. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $211.91.

Inspire Medical Systems Stock Down 3.1 %

Shares of Inspire Medical Systems stock opened at $156.87 on Thursday. Inspire Medical Systems has a 12 month low of $123.00 and a 12 month high of $225.00. The business has a fifty day simple moving average of $158.89 and a 200-day simple moving average of $178.98. The stock has a market cap of $4.67 billion, a PE ratio of 90.68, a price-to-earnings-growth ratio of 2.86 and a beta of 1.39.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, May 5th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.23) by $0.33. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. The company had revenue of $201.32 million during the quarter, compared to analysts’ expectations of $194.89 million. During the same period last year, the company posted ($0.34) earnings per share. The business’s revenue for the quarter was up 22.7% on a year-over-year basis.

Insider Buying and Selling at Inspire Medical Systems

In related news, CTO John Rondoni sold 583 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the transaction, the chief technology officer now owns 10,424 shares in the company, valued at $1,777,187.76. The trade was a 5.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Shawn Mccormick sold 360 shares of the stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $160.00, for a total value of $57,600.00. Following the sale, the director now owns 24,046 shares in the company, valued at approximately $3,847,360. This represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,527 shares of company stock worth $4,851,660 over the last three months. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Inspire Medical Systems

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of Inspire Medical Systems by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 3,270,357 shares of the company’s stock worth $606,259,000 after purchasing an additional 38,219 shares during the period. Dragoneer Investment Group LLC bought a new position in Inspire Medical Systems during the fourth quarter valued at $161,486,000. Invesco Ltd. raised its position in Inspire Medical Systems by 14.3% in the 4th quarter. Invesco Ltd. now owns 793,080 shares of the company’s stock worth $147,021,000 after purchasing an additional 99,030 shares during the period. Janus Henderson Group PLC grew its stake in shares of Inspire Medical Systems by 12.9% during the fourth quarter. Janus Henderson Group PLC now owns 567,312 shares of the company’s stock valued at $105,173,000 after buying an additional 64,703 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Inspire Medical Systems by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 486,341 shares of the company’s stock worth $90,188,000 after acquiring an additional 2,687 shares during the last quarter. Institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.